Analysis and explanation of indications, usage, dosage and precautions of Rutrombopag (Wenda)

Lusutrombopag is an oral thrombopoietin receptor agonist, mainly used for the treatment of preoperative thrombocytopenia in patients with chronic liver disease. Its mechanism of action stimulates the proliferation and differentiation of bone marrow megakaryocytes, thereby increasing the number of platelets and providing safety assurance for patients undergoing invasive surgeries. The drug is primarily indicated for patients with chronic liver disease and thrombocytopenia, especially when preparing for surgery or invasive procedures where safe levels of platelets are needed.

In terms of usage and dosage, Rutrombopag is usually administered orally once a day, and the dosage is adjusted based on the patient's weight and platelet level. The general treatment cycle is 5 to 7 days. During the treatment period, the number of platelets needs to be monitored regularly so that the medication can be stopped when the platelets reach the expected level. Excessive use may increase the risk of thrombosis, so it is important to manage dosage strictly as directed by your doctor. Preoperative platelet monitoring can help optimize surgical safety and reduce bleeding risk.

Patients need to pay attention to some safety precautions when using Rutrombopag. First of all, there is a risk of thrombosis, especially patients with a history of thrombosis or high risk factors for thrombosis, and should be used under the guidance of a doctor. Secondly, concomitant use with other thrombopoiesis-stimulating drugs or drugs that affect platelet function should be avoided to prevent excessive platelet elevation or increased bleeding risk. If adverse reactions such as headache, fatigue, increased blood pressure, or skin itching occur, medical staff should be informed promptly so that the dose can be adjusted or corresponding treatment measures can be taken.

Additionally, patients should follow a pre- and post-dose monitoring regimen. Platelet count, liver function and hematological indicators need to be tested regularly to ensure the safety and efficacy of medication. Rutrombopag is not suitable for patients with severe hepatic insufficiency or previous severe thrombotic events, and the risks need to be carefully assessed when using it. Correct medication operation, regular monitoring and individualized treatment plans can maximize the efficacy of Rutrombopag and provide safe and effective preoperative platelet management for patients with chronic liver disease.

Reference materials:https://en.wikipedia.org/wiki/Lusutrombopag